DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.
Company profile
Ticker
DRIO
Exchange
Website
CEO
Erez Raphael
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LabStyle Innovations Corp.
SEC CIK
Corporate docs
Subsidiaries
Labstyle Innovation Ltd. • PsyInnovations Inc. • DarioHealth India Services Pvt. Ltd. • Twill, Inc. ...
DRIO stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
15 May 24
EFFECT
Notice of effectiveness
9 May 24
S-3/A
Shelf registration (amended)
3 May 24
DEF 14A
Definitive proxy
1 May 24
S-3
Shelf registration
22 Apr 24
8-K
Consolidated Financial Statements
22 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
19 Apr 24
424B3
Prospectus supplement
19 Apr 24
8-K
Departure of Directors or Certain Officers
5 Apr 24
Transcripts
DRIO
Earnings call transcript
2024 Q1
15 May 24
DRIO
Earnings call transcript
2023 Q3
2 Nov 23
DRIO
Earnings call transcript
2023 Q2
10 Aug 23
DRIO
Earnings call transcript
2023 Q2
10 Aug 23
DRIO
Earnings call transcript
2023 Q1
11 May 23
DRIO
Earnings call transcript
2022 Q4
9 Mar 23
DRIO
Earnings call transcript
2022 Q3
15 Nov 22
DRIO
Earnings call transcript
2022 Q2
15 Aug 22
DRIO
Earnings call transcript
2022 Q1
12 May 22
DRIO
Earnings call transcript
2021 Q4
22 Mar 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.04 mm | 35.04 mm | 35.04 mm | 35.04 mm | 35.04 mm | 35.04 mm |
Cash burn (monthly) | 585.33 k | 326.75 k | 5.95 mm | 5.37 mm | 4.37 mm | 3.23 mm |
Cash used (since last report) | 1.21 mm | 674.64 k | 12.29 mm | 11.08 mm | 9.02 mm | 6.66 mm |
Cash remaining | 33.83 mm | 34.37 mm | 22.75 mm | 23.96 mm | 26.02 mm | 28.38 mm |
Runway (months of cash) | 57.8 | 105.2 | 3.8 | 4.5 | 6.0 | 8.8 |
Institutional ownership, Q4 2023
3.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 41 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 7.00 k |
Total shares | 1.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kershner Trading Americas,LLC | 1.05 mm | $0.00 |
North Star Investment Management | 278.00 | $0.00 |
Focused Wealth Management | 4.00 | $7.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Ben-David Zvi | Common Stock | Grant | Acquire A | No | No | 0 | 400,000 | 0.00 | 746,035 |
6 Mar 24 | Shaked Yoav | Common Stock | Grant | Acquire A | No | No | 0 | 90,000 | 0.00 | 256,193 |
6 Mar 24 | Richard Allan Anderson | Stock Option Common Stock | Grant | Acquire A | No | No | 1.68 | 320,000 | 537.60 k | 320,000 |
6 Mar 24 | Richard Allan Anderson | Stock Option Common Stock | Grant | Acquire A | No | No | 1.68 | 750,000 | 1.26 mm | 750,000 |
6 Mar 24 | Jon H. Kaplan | Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 70,000 |
6 Mar 24 | Karah Hila | Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 219,290 |
News
DarioHealth Q1 Sales $5.758M Miss $6.758M Estimate
15 May 24
Dario Signs Two Employers For Cardiometabolic Suite With Integrated GLP-1 Solution, Beginning In Q2 Of 2024
18 Apr 24
Dario Publishes Two Peer-Reviewed Studies Demonstrating Impact Of Digital Behavioral Health
10 Apr 24
Two National Employers Select Dario's Integrated Chronic Condition Solution To Improve Employee Health
2 Apr 24
Stifel Maintains Buy on DarioHealth, Maintains $4 Price Target
1 Apr 24
Press releases
DarioHealth Reports First Quarter 2024 Financial and Operating Results
15 May 24
DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th
7 May 24
Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution
18 Apr 24
Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health
10 Apr 24
Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health
2 Apr 24